^
Association details:
Biomarker:No biomarker
Cancer:Glioblastoma
Drug:carmustine (DNA synthesis inhibitor, Alkylating agent)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
05/16/2022
Excerpt:
Carmustine for Injection is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following...Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors...
Secondary therapy:
Chemotherapy
Evidence Level:
Sensitive: A1 - Approval
Published date:
07/18/2018
Excerpt:
Carmustine is effective in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery)...Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases.
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Glioblastoma...Preferred Regimen...Lomustine or carmustine.